| |
MEDIA INQUIRIES
Mike Beyer
Sam Brown Inc.
Phone:
773-463-4211
beyer@sambrown.com
|
|
PRESS RELEASES
February 27, 2013
Ceptaris Resubmits New Drug Application (NDA) to FDA for Proprietary Gel Formulation of Mechlorethamine Hydrochloride
January 30, 2013
Ceptaris Announces Publication in
JAMA Dermatology of Positive Clinical Results for
Mechlorethamine Gel in Early Stage Mycosis Fungoides, The Most
Common Type of Cutaneous T-Cell Lymphoma
October 04, 2011
FDA Accepts Filing of New Drug Application (NDA)
for Yaupon's Proprietary Gel Formulation of Mechlorethamine Hydrochloride
Yaupon seeking U.S. marketing approval for topical treatment for early stage (stages I-IIA) mycosis fungoides, a common type of Cutaneous T-Cell Lymphoma
August 11, 2011
Yaupon Therapeutics, Inc. Secures
$14.4 Million in Series D. Financing
July 28, 2011
Yaupon Therapeutics, Inc. Submits New
Drug Application for Proprietary Gel Formulation of
Mechlorethamine Hydrochloride
Requesting U.S. marketing approval for the topical treatment
of early stage (stages I-IIA) mycosis fungoides, a common type
of Cutaneous T-Cell Lymphoma
July 18, 2011
Yaupon Therapeutics, Inc. Appoints
New Management Team
New management to focus on NDA submission for proprietary gel
formulation of mechlorethamine hydrochloride to treat early
stage (stages I-IIA) mycosis fungoides, a type of Cutaneous
T-Cell Lymphoma
May 9, 2011
Yaupon Therapeutics Names Steve
Tullman Chairman and Chief Executive Officer
September 24, 2010
Yaupon Announces Results from Pivotal Study
|
|
